At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
AKTX Akari Therapeutics PLC
Market Closed 09-25 16:00:00 EDT
9.76
-0.30
-3.03%
盘后9.76
+0.000.00%
19:12 EDT
High10.25Low9.30Vol71.54K
Open10.25D1 Closing10.06Amplitude9.44%
Mkt Cap18.99MTradable Cap6.77MTotal Shares1.95M
T/O693.67KT/O Rate10.30%Tradable Shares694.50K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week
MT Newswires Live  ·  09-25 23:15
European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week
European Equities Traded in the US as American depositary Receipts Rise in Monday Trading
MT Newswires Live  ·  09-21
European Equities Traded in the US as American depositary Receipts Rise in Monday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
MT Newswires Live  ·  09-15
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading
MT Newswires Live  ·  09-10
European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
MT Newswires Live  ·  09-09
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
MT Newswires Live  ·  09-08
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
Akari Therapeutics to Present PH1 ADC Payload Platform at Oncology and Investor Conferences
Reuters  ·  09-08
Akari Therapeutics to Present PH1 ADC Payload Platform at Oncology and Investor Conferences
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
MT Newswires Live  ·  08-31
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
Akari Therapeutics Participates in Virtual Investor “Why Now” On-Demand Conference Webcast
Reuters  ·  08-27
Akari Therapeutics Participates in Virtual Investor “Why Now” On-Demand Conference Webcast
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
MT Newswires Live  ·  08-26
European Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading
MT Newswires Live  ·  08-18
European Equities Traded in the US as American Depositary Receipts Head Lower in Tuesday Trading
Akari Therapeutics - Ph1 Payload Shows Potential to Overcome Payload-Specific Resistance
THOMSON REUTERS  ·  08-18
Akari Therapeutics - Ph1 Payload Shows Potential to Overcome Payload-Specific Resistance
Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity in Urothelial Cancer Preclinical Models
THOMSON REUTERS  ·  08-18
Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity in Urothelial Cancer Preclinical Models
Akari Therapeutics - Continues to Advance Ind-Enabling Activities for Aktx-101 with Goal of Initiating Phase 1 Clinical Trial in Mid-2027
THOMSON REUTERS  ·  08-18
Akari Therapeutics - Continues to Advance Ind-Enabling Activities for Aktx-101 with Goal of Initiating Phase 1 Clinical Trial in Mid-2027
Akari Therapeutics - Developing Aktx-102 ADC Targeting Ceacam5 in Multiple Solid Tumors
THOMSON REUTERS  ·  08-18
Akari Therapeutics - Developing Aktx-102 ADC Targeting Ceacam5 in Multiple Solid Tumors
Akari Therapeutics Says AKTX-101 Shows Anti-Tumor Activity in Preclinical Urothelial Cancer Models
Reuters  ·  08-18
Akari Therapeutics Says AKTX-101 Shows Anti-Tumor Activity in Preclinical Urothelial Cancer Models
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
MT Newswires Live  ·  08-17
European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading
European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading
MT Newswires Live  ·  08-14
European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading
UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101
Reuters  ·  08-14
UK's Akari Therapeutics Q2 Net Loss Widens on Higher R&D for AKTX-101
Akari Therapeutics PLC Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14
Akari Therapeutics PLC Reports Results for the Quarter Ended June 30 - Earnings Summary

Introduction

Company Name.
Akari Therapeutics PLC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities. The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA. The company is headquartered in Boston, Massachusetts.
Issue price:
--